

Special Issue

Research in Bat-Borne Zoonotic Viruses

Message from the Guest Editors

Bats are suggested to be important reservoir hosts of many zoonotic viruses that can cross species barriers to infect humans and other domestic or wild mammals, including lyssaviruses, henipaviruses, ebolaviruses, marburgviruses, and Mers and Sars-coronaviruses. A bat origin of the recent SARS-CoV-2 (2019-nCoV), responsible for COVID-19, which started in Wuhan (China) in December 2019, has also been hypothesized. It has been assumed that bats may have a “special” relationship with viruses based on physiological, ecological, evolutionary, and/or immunological aspects, which allow them to act as special reservoir hosts for a variety of viruses that lead to efficient pathogen maintenance, evolution, and spread. In this Special Issue, we invite you to submit research papers and reviews on a wide range of research topics related to Bat-Borne Zoonotic Viruses. Topics of interest include (but are not limited to) epidemiology, diagnosis, pathogenesis, vaccines, immunology, virome of bats, genetic and antigenic characterization, viral evolution, and phylogenetic studies.

Guest Editors

Dr. Davide Lelli

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", IZSLER. Via Bianchi, 9 - 25124 Brescia, Italy.

Dr. Ana Moreno

Virology Department, Istituto Zooprofilattico Sperimentale della Lombardia ed Emilia-Romagna, Via Bianchi 9, 25124 Brescia, Italy

Deadline for manuscript submissions

closed (30 September 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/42228

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).